Epidemiology
& Biostatistics
Overview
In addition to Avalon’s core strengths in data science, statistical analysis, modelling, and data-driven analytics, the Avalon team has extensive expertise and experience in epidemiology and biostatistics. In our work in life sciences consulting, we have developed innovative approaches to the analysis of data on clinical processes, outcomes, and costs. In the development of economic models for life sciences, we have developed unique approaches beyond simple models, making use of all the value attributes of a novel drug, device, or diagnostic. We bring these same advanced statistical tools into our work in law and economics and litigation.
Types Of Engagements
- Calculation of survival, mortality, and life expectancy in personal injury cases
- Survival analysis in outcomes research
- Analysis of attributable fraction & attributable risk
- Mendelian randomization to assess causative factors in obesity
- Statistical analysis to determine causative factors & liability
- Estimation of market size for medical devices, diagnostics, & pharmaceuticals
- Novel analysis of real-world data (RWD) to support value propositions & HTA submissions
- Systematic & comprehensive summaries of literature & evidence
Key Staff
- John Schneider, PhD
- Andrew Briggs, DPhil, MSc
- Anthony LoSasso, PhD
- Robert Ohsfeldt, PhD
- Jacie Cooper, MS
Related Markets & Industries
- Insurance & Third-Party Payers
- Attorneys & Law Firms
- Medical Services
- Hospitals & Health Systems
- Pharmaceuticals & Biotechnology
- Medical Devices & Diagnostics
- Private Equity & Venture Capital
- Consumer Products
- Public Health
- Government
Related Publications
- Challenges for decision-makers when assessing within-class comparative effectiveness: the case of anticoagulation therapy for atrial fibrillation. 2022
- Estimating (quality-adjusted) life-year losses associated with deaths: With application to COVID-19. 2021
- Mendelian randomization: estimation of inpatient hospital costs attributable to obesity. 2021
- A quality of life mapping function developed from a grass pollen sublingual immunotherapy trial to a tree pollen sublingual immunotherapy trial. 2019
- Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study 2017
- Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial. 2017
- Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer 2016
- A cardiovascular disease policy model that predicts life expectancy taking into account socioeconomic deprivation. 2015
- Hospital Expenditure at the End-of-Life: What Are the Impacts of Health Status and Health Risks? 2015
- Projecting long-term graft and patient survival after transplantation. 2014
- Methods for Specifying the Target Difference in a Randomised Controlled Trial: The Difference ELicitation in TriAls (DELTA) Systematic Review. 2014
- Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review. 2014
- Population ageing and healthcare expenditure projections: new evidence from a time to death approach. 2013
Related Issue Briefs
- Attributable Risk and Attributable Fraction: Litigation Applications (Issue Brief No. 57)
- Moving Beyond ‘Lives-Saved’ From COVID-19 (Issue Brief No. 50)
- Applications of HEOR Analytics: Covariate-Adjusted Analysis of Phase 3 Clinical Trial Data of Lenvatinib versus Sorafenib in Hepatocellular Carcinoma (Issue Brief No. 47)
- Value-Based Payment for Oncology Services (Issue Brief No. 34)
- Paying for Specialty Pharmaceuticals: The Case of Injectable Oncology Drugs (Issue Brief No. 26)
- How Big a Problem is Health Care Fraud and Abuse, and How Can We Detect It? (Issue Brief No. 9)